View in EDS

A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β.

Saved in:
Bibliographic Details
Title: A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β.
Authors: Olivera I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Sanz-Pamplona R; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Oncobell Program, Catalan Institute of Cancer (ICO), Bellvitge Biomedical Research Institute (IDIBELL), CIBERESP, Hospitalet de Llobregat, Barcelona, Spain and ARAID Researcher, Aragon Health Research institute (IIS Aragon), Zaragoza, Spain., Bolaños E; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Rodriguez I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Etxeberria I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Cirella A; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Egea J; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Garasa S; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Migueliz I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Eguren-Santamaria I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Sanmamed MF; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Glez-Vaz J; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Azpilikueta A; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain., Alvarez M; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Ochoa MC; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Malacrida B; Center for tumour microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kindgom., Propper D; Center for tumour microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kindgom., de Andrea CE; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain., Berraondo P; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Balkwill FR; Center for tumour microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kindgom., Teijeira Á; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Melero I; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.
Source: Cancer discovery [Cancer Discov] 2022 Sep 02; Vol. 12 (9), pp. 2140-2157.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35771565
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Olivera+I%22">Olivera I</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Sanz-Pamplona+R%22">Sanz-Pamplona R</searchLink>; Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Oncobell Program, Catalan Institute of Cancer (ICO), Bellvitge Biomedical Research Institute (IDIBELL), CIBERESP, Hospitalet de Llobregat, Barcelona, Spain and ARAID Researcher, Aragon Health Research institute (IIS Aragon), Zaragoza, Spain.<br /><searchLink fieldCode="AU" term="%22Bolaños+E%22">Bolaños E</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Rodriguez+I%22">Rodriguez I</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Etxeberria+I%22">Etxeberria I</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Cirella+A%22">Cirella A</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Egea+J%22">Egea J</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Garasa+S%22">Garasa S</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Migueliz+I%22">Migueliz I</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Eguren-Santamaria+I%22">Eguren-Santamaria I</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Sanmamed+MF%22">Sanmamed MF</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Glez-Vaz+J%22">Glez-Vaz J</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Azpilikueta+A%22">Azpilikueta A</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.<br /><searchLink fieldCode="AU" term="%22Alvarez+M%22">Alvarez M</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Ochoa+MC%22">Ochoa MC</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Malacrida+B%22">Malacrida B</searchLink>; Center for tumour microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kindgom.<br /><searchLink fieldCode="AU" term="%22Propper+D%22">Propper D</searchLink>; Center for tumour microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kindgom.<br /><searchLink fieldCode="AU" term="%22de+Andrea+CE%22">de Andrea CE</searchLink>; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.<br /><searchLink fieldCode="AU" term="%22Berraondo+P%22">Berraondo P</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Balkwill+FR%22">Balkwill FR</searchLink>; Center for tumour microenvironment, Barts Cancer Institute, Queen Mary University of London, London, United Kindgom.<br /><searchLink fieldCode="AU" term="%22Teijeira+Á%22">Teijeira Á</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Melero+I%22">Melero I</searchLink>; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.; Navarra Institute for Health Research (IDISNA), Pamplona Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101561693%22">Cancer discovery</searchLink> [Cancer Discov] 2022 Sep 02; Vol. 12 (9), pp. 2140-2157.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101561693 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2159-8290 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221598274%22">21598274 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Discov <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35771565
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/2159-8290.CD-21-1115
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2140
    Titles:
      – TitleFull: A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Olivera I
      – PersonEntity:
          Name:
            NameFull: Sanz-Pamplona R
      – PersonEntity:
          Name:
            NameFull: Bolaños E
      – PersonEntity:
          Name:
            NameFull: Rodriguez I
      – PersonEntity:
          Name:
            NameFull: Etxeberria I
      – PersonEntity:
          Name:
            NameFull: Cirella A
      – PersonEntity:
          Name:
            NameFull: Egea J
      – PersonEntity:
          Name:
            NameFull: Garasa S
      – PersonEntity:
          Name:
            NameFull: Migueliz I
      – PersonEntity:
          Name:
            NameFull: Eguren-Santamaria I
      – PersonEntity:
          Name:
            NameFull: Sanmamed MF
      – PersonEntity:
          Name:
            NameFull: Glez-Vaz J
      – PersonEntity:
          Name:
            NameFull: Azpilikueta A
      – PersonEntity:
          Name:
            NameFull: Alvarez M
      – PersonEntity:
          Name:
            NameFull: Ochoa MC
      – PersonEntity:
          Name:
            NameFull: Malacrida B
      – PersonEntity:
          Name:
            NameFull: Propper D
      – PersonEntity:
          Name:
            NameFull: de Andrea CE
      – PersonEntity:
          Name:
            NameFull: Berraondo P
      – PersonEntity:
          Name:
            NameFull: Balkwill FR
      – PersonEntity:
          Name:
            NameFull: Teijeira Á
      – PersonEntity:
          Name:
            NameFull: Melero I
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 09
              Text: 2022 Sep 02
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2159-8290
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Cancer discovery
              Type: main
ResultId 1